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Abstract
Background: Lupus anticoagulants prolong clotting times in phospholipid-dependent coagulation
tests. Lupus Ratio assays are integrated tests for lupus anticoagulants that may be based on APTT,
RVVT or dPT clotting times. If a patient is being treated with unfractionated heparin, however, the
heparin prolong clotting times and the diagnosis of lupus anticoagulant is invalidated. Commercial
assays may have heparin neutralising agents added to their reagents. However, the type and efficacy
of the heparin neutralisation is often not documented. We wanted to test the influence and efficacy
of heparin neutralisers in the Lupus Ratio assay.
Methods: Several heparin neutralisers were tested, and polybrene was chosen for further testing.
Unfractionated heparin and/or polybrene were added to normal plasma and to plasma from
patients with or without lupus anticoagulant and clotting times compared before and after the
additions. Lupus anticoagulant-positive patients were given 5000 IU i.v. of unfractionated heparin
and plasma was collected just before and five minutes after the injection. Lupus Ratios were
calculated after polybrene was added to the postinjection samples.
Results: The Lupus Ratio became slightly lower when polybrene was added to plasma without
heparin. Plasma heparinised in vitro and plasma from patients that had received heparin, both had
Lupus Ratios nearly identical to the Lupus Ratios calculated before any additions.
Conclusion: By addition of polybrene to a final concentration of 7.9 µg/ml in test plasma, Lupus
Ratio may be determined in lupus anticoagulant-negative as well as positive plasmas irrespective of
the presence of heparin 0.0 – 1.3 U/ml.
Background
Lupus anticoagulants (LAs) are a heterogeneous group of
antibodies directed against phospholipidbinding (PL-
binding) proteins or complexes of PLs and proteins [1]. By
definition, LAs prolong clotting times in one or several PL-
dependent coagulation assays (APTT, RVVT, PT) [2,3].
The lupus ratio (LR) test is an integrated test for LA, incor-
porating screening test, mixing studies, and confirmatory
testing into one assay [4,5]. The LR test may be based on
either one of the phospholipid-dependent clotting time
assays APTT, RVVT, or dPT [4,6]. The presence of unfrac-
tionated heparin (UFH) in the sample may, however, pro-
long clotting times and thereby invalidate the diagnosis of
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UFH. 24 of these patients had false positive tests for LA in
the APTT-based LR test, and 19 of the 28 patients had false
positive tests in the RVVT-based LR test [4]. Liestøl et al.
found that heparin concentrations in plasma exceeding
0.625 U/ml gave dPT clotting times that were immeasura-
bly long in the dPT-based LR test [6].
In commercial assays, heparin neutralising agents are
often added to the reagents to avoid this problem (LA
Screen/LA Confirm, Gradipore Ltd; DVVtest/DVVconfirm,
American Diagnostica Inc.; LAC Screen/LAC Confirm,
Instrumentation Laboratory Ltd). However, the type of
heparin neutraliser is often not specified and documenta-
tion of the efficacy of the added agents not given. There
has also been some dispute on false positive test results in
samples from heparinised patients even with reagents
containing heparin neutralising agents [7,8].
Since heparin may be started on the suspicion of venous
thromboembolism only, and these patients are dis-
charged from hospital early and often followed by general
practitioners, testing for LA is often neglected. We wanted
to determine whether the inclusion of a heparin neutral-
ising substrate in the LR assay would make it suitable for
testing patients on treatment with heparin.
Methods
Normal plasma (NP)
Blood samples were collected from 30 presumably
healthy volunteers with normal APTT. The samples were
collected by venipuncture into 4.5 ml test tubes contain-
ing 0.5 ml of 0.129 M buffered sodium citrate. After cen-
trifugation at 4000 g for 20 minutes, the plasma was
pooled and stored in small aliquots at -70°C.
Heparin neutralisers
Solutions were made of hexadimethrinebromide (Poly-
brene®, Sigma Chemical Company, Saint Louis MO,
USA), poly-L-arginine (poly-L-arginine hydrochloride,
MW 15,000–70,000, Sigma), poly-L-lysine (poly-L-lysine
hydrobromide, MW 15,000–30,000, Sigma), poly-DL-
lysine (poly-DL-lysine hydrobromide, MW 1,000–4,000,
Sigma), poly-L-histidine (poly-L-histidine hydrochloride,
MW 15,000–50,000, Sigma), or protamine sulphate (Pro-
tamine® Sulphate, LEO, Ballerup, Denmark) and 0.15 M
NaCl to concentrations of 0.66 mg/ml.
For the testing of the different heparin neutralisers, each
of them was added to 0.5 ml NP to final concentrations
varying from 0.0 to 6.6 µg/ml. Clotting times were meas-
ured with APTT-reagents containing crude cephalin
diluted 1/100, 1/200, 1/800 or 1/3200. Clotting times
with each heparin neutraliser were also measured after the
addition of UFH 0.5 U/ml (final concentration) to NP.
Table 1: Influence of heparin neutraliser on the APTT. APTT clotting times were measured in NP with two reagents with crude 
cephalin diluted 1/100 and 1/3200, respectively. Mean results of two experiments and percent change in clotting time with addition of 
any heparin neutraliser are given. All experiments were performed in triplicates.
APTT, cephalin 1/100 APTT, cephalin 1/3200
mean, seconds % change mean, seconds % change
without heparin neutraliser 30.4 -- 58.7 --
Poly-L-Arginine 3.96 µg/ml 33.8 11.2 55.8 -4.94
Poly-L-Lysine 3.96 µg/ml 29.7 -2.4 79.8 36.06
Polybrene 3.96 µg/ml 34.1 12.1 72.7 23.96
Protamine 3.96 µg/ml 35.7 17.5 64.4 9.80
APTT clotting times were measured in normal plasma with two reagents with crude cephalin diluted 1/100 and 1/3200, respectively. Percent change 
in mean clotting times with addition of any heparin neutraliser are given.
Calculation of Lupus RatioFigure 1
Calculation of Lupus Ratio. Lupus Ratio (LR) may be cal-
culated from APTT, RVVT or dPT-based clotting times. A LR 
test is performed on 1:1 mixtures of patient plasma and nor-
mal plasma (NP). The clotting time is measured twice, once 
with a reagent with a low cephalin concentration (a), then 
with a reagent with a high cephalin concentration (b). The 
ratio between these clotting times is divided by the corre-
sponding ratio of NP (c:d). This final ratio is the LR of that 
plasma (a/b : c/d).
Lupus Ratio = a/b : c/d
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The clotting time of 1:1 mixture of patient plasma and NP
is determined with low and high PL concentrations,
respectively. The ratio between these two coagulation
times is normalised by dividing with the corresponding
ratio of the NP. This final ratio is the Lupus Ratio (LR) of
that plasma (Fig. 1).
APTT reagents were made from dilutions of crude cepha-
lin from bovine brain (a generous gift from Axis-Shield
PoC AS, Oslo, Norway). A constant concentration (final
concentration 6 mg/l) of ellagic acid was used as activator.
The reagents for the APTT-based Lupus Ratio test contain
crude cephalin diluted 1/100 and 1/3200 in Owren's
buffer, respectively [4]. In-house reagents for the RVVT-
based Lupus Ratio test contain crude cephalin diluted 1/
200 and 1/10000 in Owren's buffer. Russell's Viper
Venom (Sigma-Aldrich Norway A/S, Oslo, Norway) was
diluted in imidazole buffer with 1% BSA and aliquots
were stored at -20C [4,9].
After earlier testing of stability of reagents and reproduci-
bility of clotting times, the cephalin dilutions used in the
RVVT assay are made one day ahead of their use and are
stable for at least one week. The RVV was kept on ice and
was stable for 4 hours after thawing. The APTT reagents
were autoclaved and sealed and were then stable for
months.
The reference limits have been calculated earlier from a
reference population of 120 healthy blood donors [5].
The 97.5 percentile was chosen as the upper reference
limit. The upper reference limit for the APTT-based assay
was 1.05; for the RVVT-based assay it was 1.11.
Based on serial dilutions of plasma from patients with
strong LA activity, we have previously chosen arbitrary
limits for semi-quantification of LAs into weak, moderate
or strong. This semi-quantification has been shown to
have good reproducibility [5].
APTT-based Lupus Ratio in test plasma heparinised in 
vitro
Plasma from twenty patients was collected in the same
way as described for NP. The patients included twelve
patients with previously diagnosed LA and eight patients
with previous negative tests for LA.
The APTT-based LR test was performed on patient plasma
before and after the addition of 1/50 volume of polybrene
or NaCl, with a final concentration of polybrene of 7.9 µg/
ml. Patient plasma with polybrene was then tested before
and after the addition of 1 U/ml UFH (final concentra-
tion) or NaCl.
RVVT-based Lupus Ratio
Polybrene with a final concentration of 3.96 µg/ml, which
should be able to neutralise up to 0.6 U/ml heparin, and/
or UFH 0.5 U/ml (final concentration) was added to nor-
mal plasma. RVVT-based Lupus Ratios were then meas-
ured.
Polybrene (final concentration 3.96 µg/ml) and/or UFH
was also added to patient plasma from both patients with
known LA (n = 12) and plasma from patients without LA
(n = 13).
Test plasma from heparinised patients
Plasma from eleven LA positive patients had been col-
lected earlier in a study on tissue factor pathway inhibitor
in LA positive patients [10]. Informed consent was
obtained from all patients before inclusion. Blood sam-
ples were drawn before and exactly five minutes after the
intravenous injection of 5000 IU UFH. Aliquots were
stored at -70°C. The heparin concentration in post-
heparin plasma, measured as antiXa activity (Coatest®,
LMW heparin/heparin, Chromogenix AB, Mölndal, Swe-
den), ranged from 0.50 to 1.37 U/ml (individual results
not shown). Polybrene (Sigma) was added to NP to a con-
centration of 15.84 µg/ml. Patient plasma was mixed 1:1
with polybrene-containing NP. The LRs of these mixtures
were measured.
Table 2: APTT-based Lupus Ratio before and after the addition of polybrene and heparin. APTT-based Lupus Ratios were determined 
in LA-positive and LA-negative patient plasmas before and after the addition of polybrene 7.9 µg/ml and/or heparin 1.0 U/ml. APTT-
based Lupus Ratio <1.05 = negative result.
APTT-based Lupus Ratio median (range)
LA-positive patients n = 12 LA-negative patients n = 8
Lupus Ratio 1.29 (1.07 to 2.24) 0.99 (0.84 to 1.03)
Lupus ratio with polybrene 1.20 (1.01 to 2.19) 0.94 (0.82 to 1.00)
% change -5.50 (-10.85 to +1.77) -1.06 (-13.29 to +2.92)
Lupus ratio with heparin and polybrene 1.26 (1.04 to 2.22) 0.98 (0.85 to 1.00)
% change -3.52 (-6.80 to --1.10) -1.49 (-3.09 to +1.19)Page 3 of 7
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The APTT of plasma heparinised in vitro was measured
with the Thrombotrack instrument from NycoMed
Pharma. The remaining studies were performed with STA
Compact coagulation analyser from Stago Diagnostica.
Results
Choice of heparin neutraliser
Poly-L-histidine and poly-DL-lysine were not able to neu-
tralise heparin and were excluded from further testing.
The remaining four cations tested all showed a tendency
to prolongation of the APTT, particularly with the APTT-
reagent with low phospholipid concentration (table I).
The effect of poly-L-arginine seemed less predictable than
that of the others as it could both prolong and shorten the
APTT (table I). All four cations could neutralise com-
pletely the heparin effect in the APTT assays (figure 2).
Poly-L-arginine and polybrene were marginally more
effective. As the stability of polybrene is better docu-
mented, it was chosen as heparin neutraliser.
Results obtained with a thrombin time assay indicated
that 7.9 µg polybrene neutralised completely 1.2 units of
UFH (results not shown). This concentration of polybrene
was used in the following experiments. In the LR assay test
plasma is mixed with NP prior to assay. For practical pur-
poses, polybrene was added to the NP batch to a final con-
centration of 7.9 × 2 = 15.8 µg/ml, in order to obtain the
same polybrene:heparin ratio as when polybrene was
added directly to test plasma.
Heparinisation in vitro
a) Effect on APTT and the APTT-based LR
Polybrene prolonged the APTT of NP slightly (table 1),
but this prolongation was reduced or abrogated by
heparin (figure 2).
Table 2 shows the results of the APTT-based LR when
polybrene or polybrene and heparin was added to plasma
from 20 patients. The LR was somewhat lower after poly-
brene was added. This affected categorisation of some
plasma samples with LR values near discriminating val-
ues. Thus two patients switched from moderate to low
positive, and one patient from weak positive to negative.
The LR values obtained in plasma samples containing
both polybrene and heparin were very similar to baseline
values, but also here categorisation changed for three
patients with LR values near discriminating values.
b) The effect on the RVVT and the RVVT-based LR
Polybrene had little influence on the RVVT (table 3) and
the RVVT-based LR of patients with or without LA (table
4). Addition of UFH 0.5 U/ml prolonged RVVT markedly
and resulted in false positive LR results (table 4). In LA
positive samples, UFH prolonged the clotting times
beyond 120 seconds and LR could not be calculated. In
heparinised plasma, polybrene neutralised heparin and
the resulting LR values were very similar to baseline LR
values.
Heparin treated patients
The median preheparin APTT-based LR in the eleven
patients that received one injection with UFH was 1.40
(table 5). LR values with polybrene, both in heparinised
and preheparin samples, were very similar to baseline LR
Effect of heparin neutralisers on the APTT of heparinised plasmaFigure 2
Effect of heparin neutralisers on the APTT of 
heparinised plasma. a) APTT values of Na-citrate plasma 
with heparin added in vitro to a final concentration of 0.5 U/
ml. APTT reagent with cephalin 1/100 as phospholipid 
source. APTT in this heparinised plasma was unmeasurable 
without heparin neutraliser, i.e. clotting times >120 sec. The 
figure shows the clotting times when increasing concentra-
tions of the different heparin neutralisers were added. b) 
APTT values of Na-citrate plasma with heparin added to a 
final concentration of 0.5 U/ml. APTT reagent with cephalin 
1/3200 as phospholipid source. Again, APTT was >120 sec. 
when no heparin neutraliser were added. The figure shows 
the clotting times when increasing concentrations of the dif-
ferent heparin neutralisers were added.
30.2 sec.
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postheparin samples 1.32). In one patient the semi-quan-
tification changed from moderate to low positive after the
injection of heparin (table 5).
Discussion
Various polyamino acids, protamine, and polybrene are
all polycations that may neutralise the heparin effect in
clotting assays [11,12]. The polycations neutralise the neg-
atively charged heparin by forming inactive complexes
[13]. Protamine, derived from the sperm of salmon, was
the first heparin neutraliser to be described [14]. Some of
the synthetic polyamino acids may show a wider range of
neutralisation than protamine [15]. Polybrene is a syn-
thetic polymerised quaternary ammonium salt [16] and
was reported to be more stable in plasma than protamine
[11]. The chosen concentration of polybrene (7.9 µg/ml)
was able to neutralise heparin 1.2 U/ml completely. The
principle of LR has proved to give robust tests with repro-
ducible results [4-6]. When the APTT-based clotting time
results of an international interlaboratory study were used
to calculate the results according to different principles
used in LA testing, the calculation of a LR proved to give
the highest sensitivity and high concordance between the
laboratories [17]. However, heparinised plasma may give
false positive results [4,6]. The results in this report show
that the Lupus Ratio can be reliably calculated in
heparinised plasma after neutralisation with polybrene.
Polybrene prolonged the APTT somewhat, but influenced
the LR very little. Only one negative test result became
positive after the addition of polybrene, and one positive
test result became negative. In both cases the positive
results were borderline values. There were very few
changes in the categorisation of the positive test results.
Our results show that one may add polybrene to all the
NP used in the LR assays. In this way, one does not have
to use a different procedure for plasma containing UFH
compared to samples from patients that have not received
UFH.
Our LR assays are in-house tests. The reagents used in dif-
ferent in-house and commercial APTT and RVVT-based
assays for LA differ in their composition of phospholipids.
The amount and type of contact activator in the APTT-
based tests are not standardised. Therefore, the results
here may not automatically be assigned to other test sys-
tems.
Testing for lupus anticoagulant is an important part of the
evaluation of patients with venous or arterial thrombosis.
Positive test results should, however, always be confirmed
with repeated testing at least 4–6 weeks after the initial
positive finding. Repeated positive findings of antiphos-
Table 4: RVVT-based Lupus Ratio before and after the addition of polybrene and heparin. RVVT-based Lupus Ratios were determined 
in LA-positive and LA-negative patient plasmas before and after the addition of polybrene 3.96 µg/ml and/or heparin 0.5 U/ml. RVVT-
based Lupus Ratio <1.11 = negative result.
RVVT-based Lupus Ratio median (range)
LA-positive patients n = 12 LA-negative patients n = 13
Lupus Ratio 1.33 (1.14 to 1.63) 0.99 (0.88 to 1.06)
Lupus ratio with polybrene 1.36 (1.20 to 1.69) 1.03 (0.92 to 1.11)
% change 2.33 (-1.52 to +10.16) 2.94 (-1.02 to +9.57)
Lupus ratio with heparin and polybrene 1.32 (1.16 to 1.52) 1.01 (0.87 to 1.08)
% change -2.51 (-9.40 to +6.78) 1.09 (-3.03 to +5.21)
Table 3: Russel Viper Venom Times in normal plasma. RVVT were measured in NP with two different phospholipid reagents, with 
crude cephalin diluted 1/200 or 1/10 000, respectively. Addition of unfractionated heparin to plasma without polybrene gave false 
positive Lupus Ratios, while addition of heparin to plasma with polybrene gave correct result. Results are given as means of three runs. 
RVVT-based Lupus Ratio <1.11 = negative result.
Heparin concentration Polybrene concentration Mean clotting time with 
cephalin 1/200
Mean clotting time with 
cephalin 1/10 000
Lupus Ratio
0.0 U/ml 0.00 µg/ml 29.8 seconds 46.3 seconds ------
0.0 U/ml 3.96 µg/ml 30.4 seconds 48.8 seconds 1.03 (neg.)
0.5 U/ml 3.96 µg/ml 29.8 seconds 46.9 seconds 1.01 (neg.)
0.5 U/ml 0.00 µg/ml 38.1 seconds 75.4 seconds 1.27 (false pos.)
Russel Viper Venom Times were measured with two different reagents, with crude cephalin diluted 1/200 or 1/3200, respectively. Addition of 
unfractionated heparin to plasma without polybrene gave false positive Lupus Ratios, while addition of heparin to plasma with polybrene gave 
correct result. RVVT-based Lupus Ratio ≤ 1.10 = negative.Page 5 of 7
(page number not for citation purposes)
Thrombosis Journal 2006, 4:3 http://www.thrombosisjournal.com/content/4/1/3pholipid antibodies in a patient that has experienced a
thrombotic episode indicates an increased risk of recur-
rence [18,19], and prolonged treatment may be indicated.
Often these patients have not been tested before treatment
is started. Since these patients are discharged early and
subsequent care may be decentralized, postponing the
testing can mean neglected testing. Testing for LA in
heparinised plasma after neutralisation with polybrene
may ensure that the patient gets a complete evaluation of
thrombophilia factors.
Conclusion
Unfractionated heparin prolong clotting times and testing
for LA should preferably be performed in plasma without
heparin. However, in this paper we have showed that by
addition of polybrene to a final concentration of 7.9 µg/
ml in test plasma, LR may be determined in LA negative as
well as positive plasmas irrespective of the presence of
heparin 0.0 – 1.3 U/ml.
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